Navigation Links
Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
Date:6/12/2008

ising," stated Richard Lanigan, President of Cardiogenesis, "and they build upon the growing body of evidence that our Holmium YAG TMR system has a favorable impact on cell retention and survival in cardiac tissue as described by Dr. Amit Patel in a recent animal study published in Cell Transplantation. Our corporate focus is to build on this early work and provide clinicians effective tools to treat the large patient population suffering from refractory angina, be it as sole therapy or concomitant with coronary bypass."

The PHOENIX combination delivery system was CE Mark approved in November of 2006. It has been used in over 40 procedures at cardiac centers outside the U.S. It is not currently FDA approved. The Company intends to utilize the clinical experience outside the U.S. to support its clinical and regulatory strategy in the U.S.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.

For more information on the company and its products, please visit the Cardiogenesis company website at http://www.cardiogenesis.com or the direct to patient website at http://www.heartofnewlife.com.

With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statem
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
2. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
3. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
4. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
7. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
8. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
9. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
10. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
11. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced the appointment ... Warburg Pincus LLC, to the Amgen Board of Directors. ... and the deep, global experience he brings in the ... Bradway , chairman and chief executive officer of Amgen. "Fred,s breadth ... well." Mr. Hassan has been Partner and Managing ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... At Day 3 And All Subsequent Study Visits - ... Sumitomo Pharma Co., Ltd., (DSP) announced today that positive results ... treatment of patients with schizophrenia have been published in ... multicenter, placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated ...
... VRUS ) announces management will present at the ... Both conferences will be held in New York, NY. , ... will provide an overview of the company at the Goldman ... 3:10 PM (ET) and at the Needham Conference on Thursday ...
Cached Medicine Technology:Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 4Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences 2Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences 3
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source ... in Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts the ...
(Date:7/31/2015)... ... 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the ... released this new applicator in the United States as an upgrade to the CoolSmooth ... The original applicator required a 2 hour treatment time. The new CoolSmooth Pro ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... M3 USA ... excited to launch three new Board Exam Courses. , The additions of Gastroenterology, ... Board Exam Prep from MDLinx makes preparing for the exam easy and painless. ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... live lecture on pharmaceutical negligence is now available online at ( http://www.lawline.com/cle/course/its-a-wonderful-life-if-you-receive-the-right-meds-a-discussion-of-pharmaceutical-negligence ... with a 94% approval rating from the nationwide audience. The course ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... Hope IVF , is in pursuit of a visionary image that goes beyond the ... the UAE, New Hope IVF has reached extraordinary heights with dependable patient support, affordable ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3
... Israel, Nov. 29 Elbit Imaging Ltd.,(TASE, Nasdaq: ... November,28, 2007, InSightec Ltd. ("InSightec"), a subsidiary of ... an agreement for an internal,round of financing in ... existing,investors, namely: Elbit Ultrasound (Netherlands) B.V., a fully ...
... Satellite Newsfeed Notification ... Friday, 11/30, WASHINGTON, Nov. 29 , ... more than 19,million Americans. Despite its prevalence, depression ... is a,first-of-its-kind study examining the statistical relationship between ...
... benefit for the female hormone , THURSDAY, Nov. 29 ... which is often given with estrogen in hormone replacement ... U.S. researchers say. , They conducted tests on female ... come to this conclusion. , Treatment with estrogen blocked ...
... Week to Experience the, World,s Most Advanced Laparoscopic Surgery ... ... Congress, CLEVELAND, Ohio, November 29 Simbionix unveiled the,latest module ... Global Congress of Minimally Invasive Gynecology., The LAP Mentor(TM) multidisciplinary ...
... Utah, Nov. 29 Nutraceutical,International Corporation (Nasdaq: NUTR ... and year ended September 30, 2007., Net sales ... to $35.7 million for the same quarter of fiscal ... or $0.23 diluted earnings per,share, compared to net income ...
... 29 InSightec Ltd. today,reported that it has closed ... existing investors: Elbit Imaging Ltd. (Nasdaq: EMITF ), ... Company,(NYSE: GE ), MediTech Advisors LLC ("MTA"), a ... managers of the company., The investment will take ...
Cached Medicine News:Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 2Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 3Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 4Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 2Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 3Health News:Progesterone Won't Shield Women Against Alzheimer's 2Health News:Gynecologists Get First Hands-On Experience With Simbionix LAP Mentor(TM) 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 3Health News:Nutraceutical Reports 2007 Fiscal Year End Results 4Health News:Nutraceutical Reports 2007 Fiscal Year End Results 5Health News:Nutraceutical Reports 2007 Fiscal Year End Results 6Health News:InSightec Ltd. Announces US$30 Million Investment Round 2Health News:InSightec Ltd. Announces US$30 Million Investment Round 3
... Injectable Drugs is a dynamic new ... and easy to check on the ... the selected drugs, clear compatibility and ... can quickly take clinical action based ...
... Keep up with the latest in scientific ... market intelligence and knowledge resources from CenterWatch. ... to help you monitor and stay abreast ... medicine: Drugs in Clinical Trials, Clinical Trial ...
... Drug Guide for Nurses with Integrated Calculators, ... Co) is a remarkable advance in drug ... the Davis s Drug Guide (9th Edition) ... weight based medications. This product merges many ...
Make better prescribing decisions with this drug interaction analyzer containing over 3,000 brand names with generic equivalents....
Medicine Products: